Rokote Laboratories is a Finnish biotechnology company founded in 2020 through a collaboration between the University of Helsinki and the University of Eastern Finland to develop innovative medical treatments.
Subscribe to see Rokote Laboratories’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Rokote Laboratories is a drug discovery company headquartered in Finland. Xcout tracks 16 named people at Rokote Laboratories, including Erkko Ylösmäki (CEO).
10 more named people on record for Rokote Laboratories, with roles, board committees and tenure — see the full roster →
A few of Rokote Laboratories's closest competitors — see the full list of competitors and alternatives →
Kupando is a pioneering Berlin-based biopharmaceutical and biotech company headquartered in Schönefeld, Germany. The company is focused on the research and clinical development of innovative treatments to fight cancer and infectious diseases.
Raziel Therapeutics is a clinical-stage pharmaceutical company founded in 2012 and headquartered in Rehovot, Israel. The company originated from proprietary technology and collaborates internationally on medical treatments, including fat reduction therapeutics.
Baseimmune is a biotechnology research company headquartered in London, United Kingdom, pioneering active immunotherapies. The company combines cutting-edge computational design with advanced protein engineering to develop next-generation vaccines.
Retrotope, Inc. is a drug development company headquartered in Los Altos, California, focused on creating therapeutics for degenerative diseases.
Enlaza Therapeutics, Inc. is a biotechnology enterprise headquartered in California, United States. The company designs and develops next-generation covalent biologic therapeutics targeting serious diseases. It utilizes specialized proprietary discovery platforms to advance precision medicine applications.
Ahammune Biosciences is an India-based drug-discovery biotechnology company focused on developing small-molecule therapies for immune-mediated and inflammatory diseases. It serves pharmaceutical and healthcare markets by advancing novel immunomodulatory drug candidates toward clinical development.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.